Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Supportive and palliative care

1555MO - Effects of exercise on sleep quality and cancer-related fatigue during neurotoxic chemotherapy

Date

10 Sep 2022

Session

Mini Oral session: Supportive and palliative care

Topics

Supportive Care and Symptom Management;  Clinical Research;  Psychosocial Aspects of Cancer

Tumour Site

Breast Cancer

Presenters

Jana Müller

Citation

Annals of Oncology (2022) 33 (suppl_7): S713-S742. 10.1016/annonc/annonc1075

Authors

J. Müller1, C. Kreutz2, A. Schneeweiss3, G.M. Haag4, K. Steindorf2, M. Weiler5, J. Wiskemann1

Author affiliations

  • 1 Division Of Medical Oncology - Working Group Exercise Oncology, Heidelberg University Hospital - National National Center for Tumor Diseases (NCT), 69120 - Heidelberg/DE
  • 2 Division Of Physical Activity, Prevention And Cancer, DKFZ - German Cancer Research Center, 69120 - Heidelberg/DE
  • 3 Medical Oncology, Heidelberg University Hospital and German Cancer Research Center, 69120 - Heidelberg/DE
  • 4 National Center For Tumor Diseases, Dep. Of Medical Oncology, Heidelberg University Hospital, 69120 - Heidelberg/DE
  • 5 Department Of Neurology, Heidelberg University Hospital, 69120 - Heidelberg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1555MO

Background

(Neurotoxic) Chemotherapy can have extensive negative effects at the biopsychosocial level. This secondary analysis of a randomized controlled exercise intervention study aimed to investigate whether a sensorimotor- (SMT) and resistance training (RT) may affect sleep quality and fatigue during neurotoxic chemotherapy.

Methods

170 cancer patients were randomized to SMT, RT or usual care (UC). Patients in the SMT or RT group exercised 3×/week (105 min/week) during neurotoxic chemotherapy (mean length: 20 weeks). Subjectively perceived sleep quality (PSQI), fatigue (MFI), and chemotherapy-induced peripheral neuropathy (CIPN) symptoms (EORTC CIPN20) were assessed before and three weeks after last neurotoxic chemotherapy cycle. Analysis-of-covariance models were applied on changes from baseline to post-intervention assessment (covariates: age, gender, neurotoxic chemotherapy class, baseline value of the respective dependent variable, and optional CIPN symptoms).

Results

At baseline, 50% of patients reported good sleep quality. Overall sleep quality remained unchanged during chemotherapy, while general, physical, and mental fatigue increased in all groups (p<0.05). Intention-to-treat analyses (N=159) revealed no differences regarding analyzed outcomes. Exploratory per-protocol analyses (training attendance rate ≥67%; N=89) revealed that general and physical fatigue as well as reduced activity increased less during chemotherapy in the adherent exercisers (pooled group: SMT+RT) compared to UC (p≤0.02, ES≥0.47). Inclusion of CIPN symptoms as a covariate resulted in non-significant effects for all fatigue dimensions except general fatigue.

Conclusions

In a cancer population at high risk for developing CIPN, sleep quality was not affected by exercise. This result is in contrast to other research findings and might be due to the type of exercise and/or a ceiling effect. However, SMT and/or RT may alleviate several fatigue dimensions, if an appropriate training stimulus is achieved. Of note, the intervention effects on fatigue appeared to be influenced by CIPN symptoms, raising the question if the MFI is a valid PRO for detecting fatigue in CIPN patients. A methodological aspect which needs to be addressed in future research.

Clinical trial identification

NCT02871284.

Editorial acknowledgement

Legal entity responsible for the study

Heidelberg University Hospital.

Funding

This project was supported by an intramural funding programme: Proof of concept trials 3.0, National Center for Tumor Diseases, Heidelberg, Germany (G876).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.